In vitro hepatitis B virus infection of human bone marrow cells.

J B Zeldis, … , E Nir, R P Gale

*J Clin Invest.* 1986;78(2):411-417. [https://doi.org/10.1172/JCI112591](https://doi.org/10.1172/JCI112591).

Infection of humans with hepatitis B virus (HBV) frequently results in suppression of hematopoiesis; in some cases this may lead to severe bone marrow failure. The mechanism whereby HBV infection affects hematopoiesis is unknown. In vitro exposure of human bone marrow to HBV results in a dose-dependent inhibition of erythroid (erythroid burst forming units, BFU-E; erythroid colony-forming units CFU-E), myeloid (colony-forming units-granulocyte macrophage CFU-GM), and lymphoid (CFU-[T-lymphocytic]-TL) hematopoietic stem cells. Inactivation or immunoabsorption of HBV from sera resulted in loss of HBV-induced inhibition of hematopoietic stem cells. De novo gamma interferon was not detectable in the supernatants of cultures of bone marrow cells with HBV. Antibodies to gamma interferon did not affect the suppression of hematopoietic stem cells by HBV. Hepatitis B surface antigen (HBsAg) was detected by immune electron microscopy in nuclei of greater than 70% of immature hematopoietic cells including myeloblasts, normoblasts, and lymphoblasts; granulocytes had mostly cytoplasmatic HBsAg. Hepatitis B virus core antigen (HBCAg) was also detected in about 5% of HBV infected bone marrow cells by immunoperoxidase staining. These data indicate that HBV can infect hematopoietic cells and their progenitors, thus suggesting a wider range of tropism for HBV than previously reported. These results may provide a basis to study HBV infection in vitro, and the effects of HBV on hematopoiesis.
In Vitro Hepatitis B Virus Infection of Human Bone Marrow Cells

Jerome B. Zeldis, Hideo Mugishima, Howard N. Steinberg, Emanuel Nir, and Robert Peter Gale

Harvard-Thorndike Laboratory, Harvard Digestive Diseases Center, Charles A. Dana Research Institute, Divisions of Gastroenterology and Hematology/Oncology, Department of Medicine, Beth Israel Hospital and Harvard Medical School, Boston, Massachusetts 02215; Department of Medicine, Division of Hematology and Oncology, University of California at Los Angeles School of Medicine, Los Angeles, California 90024; Laboratory for Blood Morphology and Cytology, Kaplan Hospital, Rehovot, 76100 Israel

Abstract

Infection of humans with hepatitis B virus (HBV) frequently results in suppression of hematopoiesis; in some cases this may lead to severe bone marrow failure. The mechanism whereby HBV infection affects hematopoiesis is unknown. In vitro exposure of human bone marrow to HBV results in a dose-dependent inhibition of erythroid (erythroid burst forming units, BFU-E; erythroid colony-forming units CFU-E), myeloid (colony-forming units-granulocyte macrophage CFU-GM), and lymphoid (CFU-T lymphocytic-TL) hematopoietic stem cells. Inactivation or immunoabsorption of HBV from sera resulted in loss of HBV-induced inhibition of hematopoietic stem cells. De novo gamma interferon was not detectable in the supernatants of cultures of bone marrow cells with HBV. Antibodies to gamma interferon did not affect the suppression of hematopoietic stem cells by HBV. Hepatitis B surface antigen (HBsAg) was detected by electron immune microscopy in nucleoli of greater than 70% of immature hematopoietic cells including myeloblasts, normoblasts, and lymphoblasts; granulocytes had mostly cytoplasmic HBsAg. Hepatitis B virus core antigen (HBcAg) was also detected in about 5% of HBV-infected bone marrow cells by immunoperoxidase staining. These data indicate that HBV can infect hematopoietic cells and their progenitors, thus suggesting a wider range of tropism for HBV than previously reported. These results may provide a basis to study HBV infection in vitro, and the effects of HBV on hematopoiesis.

Introduction

Despite the common belief that hepatitis B virus (HBV) is exclusively hepatotropic, recent evidence suggests that HBV can infect human hematopoietic cells. Romet-Lemonne and colleagues found that a small percentage of bone marrow cells from four HBV-infected patients contained hepatitis B virus surface antigen (HBsAg) and hepatitis B core antigen (HBcAg). In addition, they established an HBV-containing lymphoblastoid cell line from the bone marrow of a patient with HBV infection (1). Others have identified HBV DNA sequences in the peripheral blood cells of patients with HBV infection (2, 3) and in patients with acquired immunodeficiency syndrome (AIDS) (4). Infection of hematopoietic cells by HBV may explain the moderate bone marrow failure as well as the rare cases of aplastic anemia observed in patients with HBV infection (5). To determine the mechanism whereby HBV inhibits normal hematopoiesis, we studied the effect of HBV on the growth of bone marrow progenitor cells in vitro. Normal bone marrow cells (MNC) were exposed to HBV-containing sera and cultured to determine the effect of HBV infection on five classes of hematopoietic stem cells including granulocyte/macrophage (CFU-GM), erythroid (CFU-E, BFU-E), T lymphocyte (CFU-TL), and pluripotent (CFU-GEMM) progenitor cells. Bone marrow cells exposed to HBV were also analyzed by immune electron microscopy for HBsAg and by immunoperoxidase staining for HBcAg. Our results suggest a direct effect of HBV on human bone marrow progenitor cells and may provide a model for studying HBV-induced bone marrow suppression and HBV infection of human bone marrow cells.

Methods

HBV DNA. pHBV-1, a gift of Dr. Jesse Summers (Fox Chase Cancer Institute), contains the entire genome of an adw hepatitis B virus inserted in the Eco RI restriction site of PBR322. HBV DNA free of PBR322 vector sequences was purified by preparative electrophoresis of Eco RI digested pHBV-1.

Sera. Serum specimens were obtained from healthy human volunteers with no history of HBV exposure and who lacked serologic evidence of previous or current HBV infection. HBsAg and HBV DNA positive serum samples were obtained from patients with chronic active hepatitis (3), asymptomatic carrier state (2), and acute hepatitis B (1). HBV DNA negative samples were obtained from patients with non-A, non-B chronic active hepatitis (1), acute hepatitis A (1), acute Epstein Barr virus hepatitis (1), hepatocellular carcinoma (1), and HBsAg positive postnecrotic cirrhosis (1). Sera were filtered with 0.22-μm millipore-GU filter unit (Millipore Corp., Bedford, MA) and stored at -20°C.

pluripotent cells; CFU-GM, CFU-granulocyte/macrophage; CFU-TL, CFU-T lymphocytic cells; FACS, fluocrescent activated cell sorter; FITC, fluorescein isothiocyanate; HBcAg, hepatitis B virus core antigen; HBsAg, Hepatitis B virus surface antigen; HBV, hepatitis B virus; 2ME, 2-mercaptoethanol; MNC, human bone marrow mononuclear cells; PAP, peroxidase antiperoxide; PHA-LCM, phytohemagglutinin-stimulated leukocyte-conditioned medium; SSC, standard saline citrate.

Hepatitis B Virus Inhibition of Myeloid Differentiation 411
Bone marrow. Human bone marrow was aspirated from the iliac crest of normal donors for bone marrow transplantation or from ribs obtained at thoracotomy. Informed consent as approved by an Institutional Review Board was obtained from all donors. Bone marrow donors had no serologic evidence of hepatitis or previous HBV infection.

Bone marrow inhibition assay. Bone marrow mononuclear cells were isolated by Ficoll-Hypaque density centrifugation and suspended in RPMI 1640 supplemented with 10% heat inactivated (56°C for 30 min) fetal calf serum (FCS). 5 x 10^6 MNC in 50 μl were incubated with 150 μl of serial log_{10} dilutions of human sera at 37°C in 5% CO_2 atmosphere for 20 h. The cells were harvested, washed three times, and assayed for CFU-GM, CFU-TL, BFU-E, CFU-E, and CFU-GEMM as follows:

- **CFU-GM**: 2 x 10^5 MNC were assayed for CFU-GM in minimal essential medium (MEM)-alpha medium (Irvine Scientific, Irvine, CA), containing 0.3% agar, 20% FCS, and 10% phytohemagglutinin-stimulated leukocyte conditioned medium (PHA-LCM). CFU-GM were scored after 10 d of culture with colonies consisting of greater than 40 cells.
- **CFU-TL**: 1 x 10^5 MNC were plated in enriched MEM-alpha medium containing 20% FCS, 15% bovine serum albumin (BSA), 5 x 10^{-3} 2-mercaptoethanol (2ME), and 20% interleukin 2 (IL-2). Colonies were scored after 7 d.
- **CFU-E**: BFU-E and CFU-GEMM. 2 x 10^5 MNC were cultured in Iscove's modified Dulbecco's medium in the presence of 0.8% methylcellulose, 30% FCS; 10% PHA-LCM, 1% deionized BSA (Sigma, St. Louis, MO) 5 x 10^{-3} 2ME and 2 μl/ml erythropoietin (Green Cross, Tokyo, Japan) for BFU-E and CFU-GEMM and 0.3 U/ml erythropoietin for CFU-E. BFU-E and CFU-GEMM were scored after 14 and 16 d of culture, respectively. CFU-E were scored after 7 d of culture.

Each assay consisted of 1 ml of the respective mixture plated in duplicate in 35-mm LUX tissue culture dishes (Miles Laboratories, Naperville, IL) and incubated at 37°C in 5% CO_2 and 95% humidity. The number of colonies formed from bone marrow incubated with HBV were compared to that incubated with normal AB+ control serum and the data expressed as percent inhibition. Each assay was run in triplicate and the results are reported as the mean number of colonies for a particular dilution of serum.

Inactivation of HBV+ Sera

Heat inactivation. 1 ml of sera was incubated in a 100°C water bath in an Eppendorf centrifuge tube for 1 min and then allowed to cool to room temperature.

Urea dialysis. Sera were placed in a dialysis membrane and dialyzed against 4 M urea or phosphate-buffered saline (PBS) for 48 h with two changes of dialysate, and then against three changes of PBS.

Immunoadsorption of HBsAg and HBV DNA. The HBsAg+ HBV DNA+ serum was repeatedly immunoadsorbed to a mouse monoclonal anti-HBs Sepharose column until >95% of the HBsAg was removed from the eluate as judged by endpoint titration of serial dilutions in an immunoblot assay for HBsAg. The serum eluate was concentrated to the original volume and sterilized by 0.22 μm filtration. The column was washed with 10 vol of PBS and eluted with a pH 2.4 glycine-HCl buffer. The eluate was neutralized, dialyzed against PBS, and concentrated to the original volume. The immunoadsorbed serum was demonstrated to have no HBV DNA by dot-blot analysis and <95% of initial HBsAg concentration. In contrast, the eluate had both HBsAg and HBV DNA. The mouse monoclonal anti-HBs Sepharose column was the gift of Dr. Jack Wands.

Absorption of sera with bone marrow cells. 5 x 10^5 MNC in RPMI 1640 were incubated with an equal volume of sera for 2 h at 4°C. The cells were pelleted at 400 g and the supernatant removed.

Monoclonal anti-gamma interferon antibodies. Monoclonal anti-gamma interferon antibodies with a neutralizing effect of 1,600 nU/unit gamma interferon were obtained from Dr. Jan T. Vilecek (7). Bone marrow cells were incubated with HBV+ serum and a volume of antibody capable of neutralizing 40 U/ml of gamma interferon. After 20 h of incubation, the MNC were washed twice and assayed for CFU-E and CFU-GM as described.

HBV DNA assay

The sensitivity of this assay is 2.8 x 10^3 HBV DNA molecules per 50 μl serum. The preparation of the serum samples was performed as described (8), Biodyne Nylon Membrane (PALL-Ultra Fine Corp, Glen Cove, NY) was used instead of nitrocellulose. The membranes were prehybridized and hybridized to 32P-labeled HBV DNA by standard techniques (9). The filters were washed at room temperature with 2 x standard saline citrate (SSC) (1 x SSC = 0.15 M NaCl, 0.015 M sodium citrate pH 7.0) with 0.5% SDS for 5 min, then 2 x SSC with 0.1% sodium dodecyl sulfate (SDS) for 15 min, then twice in 0.1 x SSC with 0.5% SDS at 68°C for 1 h each. The filters were air-dried and autoradiographed overnight and for 7 d at -70°C using Kodak X-Omat XAR film (Eastman Kodak Co., Rochester, NY) and a Cronex Lightning-Plus enhancing screen (DuPont, Wilmington, DE). 32P-labeled HBV DNA were produced by nick translation using standard techniques (9). The 32P-labeled HBV DNA probe (sp act 1-4 x 10^6 cpm/μg DNA) did not cross hybridize with pBR322 DNA.

Fluorescent activated cell sorter (FACS) analysis of human bone marrow cells

After 20 h incubation with HBV or control serum, 1 x 10^5 MNC were washed twice with 0.1% sodium azide (NaN_3) and incubated with 200 μl of mouse monoclonal anti-HBs antibody (1:100) or an identical class of murine hybridoma protein (5 μg) without anti-HBs activity for 45 min at 24°C, then washed with PBS with NaN_3, 200 μl of fluorescein isothiocyanate (FITC)-conjugated goat antimouse IgG antibody (Tago, Burlingame, CA) was added and the cells incubated at 4°C for 45 min. Cells were washed and resuspended in 1 ml of PBS with NaN_3. Samples were examined with FACS (Cytofluorograph 504, Ortho, Raritan, NJ). The murine monoclonal antibodies were the gift of Dr. Jack Wands.

Immune electronmicroscopy of MNC

1 x 10^5 bone marrow cells were incubated for 20 h with sera as described above. Samples were washed twice with RPMI 1640 medium and incubated with murine monoclonal anti-HBs (diluted 1:100) for 45 min. Cells were washed and fixed for 10 min with Karnovsky fixative (10) and analyzed. For surface labeling, cells were washed and incubated for 1 h with 150 μl of goat antimouse immunoglobulin linked to colloidal gold particles (size:20 nm) (GAMG 20 Janssen Pharmaceuticals N.V.B-2340, Beersel-Belgium, diluted 1:1), washed and refixed for 24 h or more prior to myeloperoxidase staining (11). For intracellular labeling, cells were treated with Karnovsky fixative for 24 h and embedded. Ultra-thin sections were labeled with GAMG-20 for 15 min and stained with uranyl acetate.

Preparations were examined with an electron microscope. Black grains appeared in cells containing HBsAg.

Immunoperoxidase detection of HBcAg

1 x 10^5 MNC were incubated with sera as described above and then transferred to a microscope slide using a cytopsin (Shandon-Southern, England). They were then stained for HBcAg by the protocol and reagents of the DAKO peroxidase antiperoxidase (PAP) kit for HBCAg (DAKO Corp., Santa Barbara, CA) (12). Samples were air-dried, incubated with 3% H_2O_2 in methanol for 5 min to inactivate endogenous peroxidase. Slides were rinsed with 0.05 M Tris buffer (pH 7.6) and incubated with rabbit anti-HBc or nonimmune rabbit serum for 20 min. Cells were washed again with Tris buffer and incubated with a swine antirabbit immunoglobulin for 20 min, rinsed, and incubated with soluble horseradish peroxidase rabbit anti-horseradish peroxidase complex for 20 min. Samples were incubated with the peroxidase substrate containing 3-amin-9-ethylcarbazole, 0.1 M acetate buffer and 0.3% H_2O_2 before counterstaining with hematoxylin to demonstrate nuclei.

Results

Co-culture of human bone marrow mononuclear cells (MNC) with HBV containing sera resulted in a dose-dependent inhib-
Inhibition of the five types of stem cells studied. For example, exposure of bone marrow cells to an undiluted HBV DNA positive serum resulted in suppression of CFU-GM, BFU-E, and CFU-TL colony formation by 65±3, 46±6, and 49±3%, respectively, compared with controls (Fig. 1). Although the absolute number of colonies in each assay varied for different bone marrow specimens, percent inhibition was internally consistent for each experiment. Incubation of bone marrow cells with serial log10 dilutions of HBV containing sera resulted in the gradual loss of the HBV-mediated suppression. Inhibition of CFU-GM and CFU-TL was still observed using sera diluted 1:100. Other sera that had higher concentrations of HBV DNA inhibited the number of CFU-GM and BFU-E by as much as 100% compared to control (data not shown). CFU-E was also inhibited by HBV DNA+ sera. Undiluted HBV DNA+ sera from three patients inhibited CFU-E by 38±7, 72±3, and 100±0%. In a preliminary study, CFU-GEMM was also found to be inhibited by 75% of control by undiluted HBV serum. (Exposure to control serum gave 8±2 colonies per 2 X 105 MNC, while undiluted HBV sera produced 2±1 CFU-GEMM per 2 X 105 MNC.)

The effect of preincubation time on subsequent BFU-E colony formation by two different HBV DNA containing sera is illustrated in Fig. 2. Although no inhibition of BFU-E was observed after 3 h of preincubation with undiluted serum 1, complete suppression was seen after 20 h preincubation of undiluted serum but not serum diluted 1:10. Serum 2, which contained a tenfold higher concentration of HBV DNA, completely inhibited BFU-E after 3 h incubation when undiluted, but not at a 1:1,000 dilution. Similar results were obtained with CFU-GM and CFU-E.

Nine HBV DNA negative sera from patients with chronic non-A, non-B hepatitis, hepatitis A, Epstein-Barr virus-related hepatitis, hepatoma and healthy normal volunteers had no significant effect on hematopoietic stem cells (<20% inhibition). In these experiments, significant inhibition of CFU-GM assay by >30% correlated with the presence in serum of HBV DNA sequences. CFU-GM were inhibited by all HBV DNA positive sera whether or not circulating mononuclear cells from the patient contained HBV DNA (Table I).

To determine if the HBV virion is responsible for inhibition of CFU-GM, HBV DNA positive sera were treated to inactivate or remove infectious HBV by three techniques: (a) heat (1 min at 98°C); (b) dialysis against 4 M urea; and (c) removal of HBV using a mouse monoclonal anti-HBs affinity column. The effect of these treatments on HBV mediated suppression of CFU-GM are shown in Fig. 3. Both heat inactivation and urea dialysis, which eliminate infectivity of HBV, removed the inhibitory effect.

![Figure 1](image1.png)
**Figure 1.** Effect on hematopoietic colony formation of incubating MNC with serum containing HBV DNA. The data charted are the mean inhibitions and SEM of colony formation produced by exposure to a HBV DNA+ serum compared to the number of colonies of a negative control serum (see Methods). The serial log10 dilutions of sera were made in RPMI 1640 media. The number of colonies for the control serum for CFU-GM was 228±8 (95% CI) per 10^5 cells; for BFU-E, 230±4; and for CFU-TL, 1,228±41.

![Figure 2](image2.png)
**Figure 2.** The effect of two HBV DNA+ sera on BFU-E after a 3- and 24-h preincubation. MNC were incubated with AB+ control serum or HBV DNA+ sera for 3 or 24 h; washed four times and plated into the BFU-E assay as described in the methods. Plotted are the mean values of three simultaneous determinations and the SEM. The sera used in the 3 h incubation were diluted 1:1. The mean colony number and the 95% CI for the 3-h control was 13.9±3.2 per 10^5 cells and for the 24-h control, 58.6±13.4.

<table>
<thead>
<tr>
<th>Table I. Inhibition of CFU-GM by Sera</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient</td>
</tr>
<tr>
<td>---------</td>
</tr>
<tr>
<td>1</td>
</tr>
<tr>
<td>2</td>
</tr>
<tr>
<td>3</td>
</tr>
<tr>
<td>4</td>
</tr>
<tr>
<td>5</td>
</tr>
<tr>
<td>6</td>
</tr>
<tr>
<td>7</td>
</tr>
<tr>
<td>8</td>
</tr>
<tr>
<td>9</td>
</tr>
<tr>
<td>10</td>
</tr>
<tr>
<td>11</td>
</tr>
</tbody>
</table>

* HBV DNA determined from 50 μl of sera by a dot blot technique described in Methods. +, HBV DNA positive; −, no detectable HBV DNA after 7 d autorgraphy. +HBV DNA was assayed by extracting DNA from mononuclear fraction of a Ficoll-Hypaque fraction of peripheral blood; shearing the DNA, electrophoresing the DNA in 0.7% agarose, Southern blotting to nitrocellulose (NC) and exposing the NC filter to radioactive HBV DNA probes (2).

† Inhibition of <20% was considered not statistically significant. Each value is the mean of three measurements with the same undiluted serum. Listed are the percentage inhibition and the standard error of the mean. The control serum produced 157±5.6 colonies per 2 X 10^5 cells.
of HBV DNA positive sera on CFU-GM. In contrast, dialysis of HBV DNA+ sera against PBS did not suppress CFU-GM. Serum depleted of HBV DNA following passage through an anti-HBs immunoabsorption column no longer inhibited CFU-GM. The HBV DNA containing eluate recovered from the column markedly suppressed CFU-GM. The inhibitory activity of HBV containing sera thus coincided with HBV infectivity and the presence of HBsAg immunoreactivity and of HBV DNA.

To investigate whether antibodies to HLA might account for inhibition of CFU-GM, HBV DNA+ serum was absorbed against bone marrow cells from the same donor used in the stem cell assays. Preabsorption did not abrogate the inhibitory effect of HBV DNA+ serum on CFU-GM. Additional evidence against a role of anti-HLA antibodies is the finding that the same serum inhibited progenitors from individuals of different HLA types and that different HBV DNA+ sera inhibited bone marrow from a single donor. As indicated, HBV DNA− sera from individuals had no effect on CFU-GM.

Gamma interferon can inhibit CFU-GM in vitro (13) and may play a role in the suppression of hematopoiesis in some cases of aplastic anemia (14, 15). The HBV DNA+ sera we studied typically contained 5−15 U/ml of gamma interferon vs. 5 U/ml in normal sera (as determined by the VSV/WISH assay [16]). It was therefore necessary to determine whether the observed inhibition of bone marrow progenitor cells with HBV DNA+ sera was mediated by gamma interferon. Incubation of HBV DNA+ serum with a monoclonal anti-gamma interferon antibody prior to addition of bone marrow cells did not affect the serum's ability to inhibit CFU-GM or CFU-E colony formation (Fig. 4). Furthermore, preincubation of bone marrow cells with 10 to 1,000 U/ml gamma interferon for 20 h did not alter the number of CFU-GM (data not shown). Finally, the concentration of gamma interferon recovered from these cultures decreased with incubation time consistent with the conclusion that gamma interferon was not induced during culture of bone marrow cells with HBV.

Having established that HBV can inhibit hematopoiesis in vitro, we next determined if HBV-associated antigens could be detected in bone marrow cells exposed to HBV containing sera. Bone marrow was incubated with HBV DNA+ sera, washed, incubated with murine anti-HBs antibodies or hyperimmune anti-HBs sera, and examined for indirect immunofluorescence by fluorescence microscopy or using a FACS. 1−2% of MNC co-cultured with HBV containing sera exhibited surface fluorescence for HBsAg by indirect immunofluorescence; cells either incubated with normal control sera or stored with sera without anti-HBs activity were negative. FACS analysis indicated that the HBV-infected bone marrow cells incubated with anti-HBs murine monoclonal antibodies contained a substantial population (5%) of brightly fluorescent positive cells. Only MNC incubated with HBV-containing sera and stained with anti-HBs monoclonal antibody exhibited fluorescence in a size population of cells consistent with hematopoietic cells. No fluorescence was observed either in MNC incubated with HBV DNA− AB serum and stained with anti-HBs or in MNC incubated with HBV DNA+ sera and stained with control monoclonal antibody with no anti-HBs activity.

To better define the population of MNC containing viral antigens, immunoelectron microscopic analyses of bone marrow cells cultured with and without HBV DNA+ serum were performed. Surface labeling with murine monoclonal anti-HBs antibodies was only observed in <10% of the myeloperoxidase-positive myeloblasts and myelocytes. Lymphocytes and erythrocyte precursors did not have HBsAg on their surface. In contrast, intracellular labeling with monoclonal anti-HBs antibodies was detected in nuclei and cytoplasm of all nucleated cells examined. The labeling pattern of the nucleus and cytoplasm was different among the various hematopoietic cell types (Table II). Greater than 70% of nuclei of myeloblasts, normoblasts, and lymphocytes were HBsAg+; granulocytes contained predomi-
Bone marrow cells incubated with HBV DNA+ sera were assayed for HBcAg by the PAP technique. HBcAg was detected in MNC incubated with HBV+ sera but not in controls. About 5% of cells stained positive for HBcAg.

**Discussion**

HBV infections are associated with mild suppression of hematopoiesis and rarely with cases of severe aplastic anemia. Our investigations of the in vitro effects of HBV on colony formation may provide a model to investigate these phenomena. Our studies indicate that suppression of hematopoiesis in vitro is directly related to an effect of HBV on hematopoietic progenitor cells. Exposure of bone marrow cells to HBV DNA+ sera results in the in vitro suppression of erythroid (CFU-E; BFU-E), myeloid (CFU-GM), and lymphoid (CFU-TL). Preliminary data also suggest an effect on pluripotential (CFU-GEMM) stem cell growth. Viral inactivation studies (Fig. 3) and serial dilution of HBV DNA+ sera suggest that the inhibitory effect of HBV is mediated by infectious virions ("Dane particles"). Sera that lacked HBV DNA but contained HBsAg, corresponding to the noninfectious "22-nm particles" and "pencil shapes," had no effect on bone marrow progenitors. Inactivation of HBV DNA+ sera by heat or 4 M urea treatment that eliminate the infectivity but not the immunogenicity of HBV, resulted in the loss of CFU-GM inhibition. Removal of viral particles by immunoabsorption using an anti-HBs column similarly eliminated CFU-GM inhibition. Exposure of HBV DNA+ serum to anti-gamma interferon antibodies did not alter inhibition of CFU-E and CFU-

**Table II. Distribution of HBsAg in Cytoplasm and Nucleus of Different Hemopoietic Cells as Determined by a Gold Label*  

<table>
<thead>
<tr>
<th>Cell</th>
<th>Cytoplasm labeling</th>
<th>Nuclear labeling</th>
</tr>
</thead>
<tbody>
<tr>
<td>Myeloblasts</td>
<td>20</td>
<td>80</td>
</tr>
<tr>
<td>Promyelocytes and myelocytes</td>
<td>50</td>
<td>50</td>
</tr>
<tr>
<td>Metamyelocytes</td>
<td>55</td>
<td>45</td>
</tr>
<tr>
<td>Granulocytes</td>
<td>76</td>
<td>24</td>
</tr>
<tr>
<td>Normoblasts</td>
<td>30</td>
<td>70</td>
</tr>
<tr>
<td>Lymphocytes</td>
<td>15</td>
<td>85</td>
</tr>
<tr>
<td>Red blood cells</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

* MNC incubated with control sera instead of HBV DNA+ sera did not have two or more gold particle clusters. Data are expressed as the percentage of 50 cells of each type of bone marrow cell that contained clusters of gold particles.

nantly cytoplasmic HBsAg. Mature erythrocytes which lack nuclei, contained no HBsAg. Fig. 5 illustrates cytoplasmic and nuclear HBsAg detected by immunoelectron microscopy. Although the density of HBsAg detected in the MNC was low, results were reproducible. Furthermore, MNC preincubated with sera from healthy controls or MNC incubated with a control murine myeloma protein were negative. Intracellular inclusions resembling virions or core particles were not seen on electronmicroscopy of MNC incubated for 24 h with HBV.

**Figure 5.** Immune electron microscopy of bone marrow mononuclear cells incubated with HBV DNA+ serum. (A) Myeloperoxidase positive myelocyte with gold particles on the surface (× 4,500); (B) Myeloblast with nuclear labeling (× 14,000); (C) Neutrophil with both cytoplasmic and nuclear labeling (× 4,500); and (D) normoblast with nuclear labeling (× 20,000). Only MNC incubated with HBV and stained with murine monoclonal anti-HBs antibodies had clusters of two or more gold particles. MNC incubated with HBV and stained with nonspecific monoclonal antibody or MNC incubated with control sera and stained with monoclonal anti-HBs antibodies did not have clusters of gold particles.
GM, suggesting that gamma interferon does not play a role in this process. These results are consistent with the hypothesis of a direct effect of HBV on hematopoietic stem cells.

Demonstration of both HBsAg and HBCAg in the cytoplasm and nucleus of mature and immature bone marrow mononuclear cells is consistent with the hypothesis that the virus is able to infect hematopoietic cells. FACS analysis demonstrated that ~5% of MNC have HBsAg on their surface. This may be due to HBV binding to receptors on the hematopoietic cells. Whether there is viral replication or active transcription in these cells is unknown but is presently under study. The absence of intracellular virus and core particles on electron microscopy makes it unlikely that active viral production was completed during the 20-h incubation of bone marrow cells with HBV. Recent work with the duck hepatitis virus, another hepatitis virus, indicated that at least 6 d are needed before viral assembly occurs. These studies and others recently reported investigations extend the range of tropism of HBV in man (1–3, 17, 18). Recently, Laure et al. (4) demonstrated that T cell clones derived from AIDS patients contain HBV DNA.

In addition to HBV, other types of acute viral infections, including non-A, non-B hepatitis, hepatitis A, and Epstein-Barr virus hepatitis are associated with bone marrow suppression. However, sera from patients with these infections have no effect on bone marrow progenitor cells. Their inability to suppress bone marrow progenitor cells may be related to the presence of low concentrations of virus. Indeed, it has been shown that during the clinical phase of acute hepatitis A infection, the serum concentration of virus is very low. The lack of an inhibitory effect by sera of patients with other infectious agents may be analogous to the gradual loss of inhibition observed with the serial dilution of HBV DNA + sera.

In their study of a parvovirus-like agent and its effect on hematopoiesis, Young et al. reported that acute phase sera from patients with HBV-associated hepatitis failed to inhibit bone marrow progenitor cells in vitro (19). This lack of effect may be attributed to the exposure of bone marrow cells only to a 1:100 dilution of sera. As demonstrated in Figs. 1 and 2, the inhibitory effect of HBV on hematopoiesis may be readily diluted out at a 1:100 concentration of sera containing only a moderate amount of HBV DNA. Sera that contain the parvovirus-like agent described by Young et al. (19) inhibit CFU-E at greater dilutions than sera that contain HBV. The greater potency of the parvovirus-like agent containing sera may be a reflection of a higher concentration of active virus in serum as compared to that of HBV.

Gamma interferon has been demonstrated to be produced by the peripheral blood mononuclear cells of patients who have aplastic anemia. Some patients with aplastic anemia also have very high concentrations of gamma interferon in their serum. This has led to the hypothesis that gamma interferon may be a mediator of the hematopoietic suppression that occurs in aplastic anemia (14, 15). However, our results suggest that HBV suppression of colony formation is not mediated by gamma interferon. The addition of monoclonal anti-gamma interferon antibody did not affect HBV suppression of CFU-E and CFU-GM. It should be emphasized furthermore, that bone marrow cells were preincubated with HBV sera prior to cell culture, and thus only exposed to low levels of gamma interferon (10–20 U/ml) for 18 to 24 h. We have demonstrated that preincubation of bone marrow cells with gamma interferon up to 1,000 U/ml did not affect colony formation. These results are similar to those reported by Toretsky et al. (20) who showed that transient exposure to bone marrow cells to gamma interferon did not significantly suppress colony formation. A dose-dependent suppression of colony formation was only observed when gamma interferon was added in continuous culture to bone marrow cells (unpublished observations, 13, 15, 20).

Though both alpha and gamma interferon are induced by acute viral infections, a putative role for alpha interferon in HBV suppression of hemopoiesis was not studied. It should be noted that the dose-response suppression of colony formation by alpha interferon is similar to gamma interferon for CFU-GEMM, BFU-E, and day 7 CFU-GM. Day 14 CFU-GM, which were assayed in the present study, were significantly less sensitive to alpha interferon (13). Thus, while alpha interferon’s role in the suppression of hematopoiesis observed by HBV in vitro cannot be excluded, it is unlikely.

Since hematopoietic cells are easily obtained, and because there are extensive in vivo and in vitro data regarding their growth, progenitor-progeny relationships, and growth-factor requirements, the effects of HBV on bone marrow progenitor cells can be readily studied in vitro. To date, there is no in vitro model to examine HBV infection of human hepatocytes and hepatoma cells. The infection of human bone marrow cells with HBV thus may provide a model to study the cellular and molecular events associated with HBV infection.

Acknowledgments

Dr. Susan Wormsley (Cytokinetica, La Jolla, CA), performed the cytofluorographic analyses; Dr. Annette Maluish (National Cancer Institute/FCRC, Frederick, MD), the analysis of gamma-interferon; Dr. Jack Wands (Massachusetts General Hospital, Boston, MA) donated the murine monoclonal antibodies and the murine monoclonal anti-HBs Sepharose column; and Mr. T. Shimron assisted with the electron microscopy. Dr. Robertson Parkman provided the gold-linked antibody. Neutralizing monoclonal antibody to gamma-interferon was kindly provided by Dr. Jan T. Vilecek (New York University Medical Center). Supported in part by grant CA23175 and CA33012 from the National Cancer Institute. Dr. J. Zeldis is a Pfizer postdoctoral fellow. Dr. H. Steinberg is the recipient of a Leukemia Society of America Special Fellowship Award.

References


